Overall response to anti-IL5/anti-IL5Ra treatment in severe asthma does not depend on initial bronchodilator responsiveness
C. Mümmler (München, Germany), H. Suhling (Hannover, Germany), N. Kneidinger (München, Germany), R. Buhl (Mainz, Germany), M. Kayser (Hannover, Germany), N. Drick (Hannover, Germany), J. Behr (München, Germany), T. Welte (Hannover, Germany), S. Korn (Mainz, Germany), K. Milger (München, Germany)
Source: International Congress 2022 – Allergy and asthma: biomarkers, phenotypes and real-world evidence
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Mümmler (München, Germany), H. Suhling (Hannover, Germany), N. Kneidinger (München, Germany), R. Buhl (Mainz, Germany), M. Kayser (Hannover, Germany), N. Drick (Hannover, Germany), J. Behr (München, Germany), T. Welte (Hannover, Germany), S. Korn (Mainz, Germany), K. Milger (München, Germany). Overall response to anti-IL5/anti-IL5Ra treatment in severe asthma does not depend on initial bronchodilator responsiveness. 1687
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|